Abstract
Chronic obstructive pulmonary disease (COPD) causes significant mortality in Japan. GFF MDI is a long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combination of glycopyrronium (GP) and formoterol fumarate dihydrate (FF), delivered by a metered dose inhaler (MDI) using co-suspension delivery technology, for the long-term maintenance treatment of COPD. This randomized, Phase I, single-dose, four-treatment, four-period, crossover study (NCT02196714) examined the pharmacokinetic (PK) and safety profile of two doses of GFF MDI (28.8 μg/10 μg and 14.4 μg/10 μg) and two doses of GP MDI (28.8 μg and 14.4 μg), both formulated using co-suspension delivery technology, in healthy Japanese subjects (18-45 years of age). PK parameters included area under the curve (AUC) from 0 to 12 h (AUC0-12), AUC from 0 to the time of the last measurable plasma concentration, maximum observed plasma concentration (Cmax), and time to Cmax. Safety was monitored throughout the study. Plasma GP profiles were comparable between GFF MDI and GP MDI formulations containing the same GP dose. Increases in GP AUC0-12 and Cmax were generally dose proportional from 14.4 to 28.8 μg after administration of either formulation. The addition of FF 10 μg ...Continue Reading
References
Dec 23, 2004·Respirology : Official Journal of the Asian Pacific Society of Respirology·Yoshinosuke FukuchiCarol Zaher
Jun 19, 2007·American Journal of Respiratory and Critical Care Medicine·Nanshan ZhongPixin Ran
Oct 19, 2007·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Timothy H SelfHeather Swanson
Jun 11, 2008·Clinical Cardiology·Akira FunadaMasakazu Yamagishi
Jul 11, 2008·Clinical Pharmacology and Therapeutics·S U YasudaS-M Huang
Jan 16, 2009·Respirology : Official Journal of the Asian Pacific Society of Respirology·Wan C TanNan-Shan Zhong
Jan 1, 2010·Basic & Clinical Pharmacology & Toxicology·Achiel Van Peer
Jan 20, 2012·International Journal of Clinical Pharmacology and Therapeutics·Romain SechaudGuenther Kaiser
Sep 14, 2012·The AAPS Journal·Barbara M DavitLawrence X Yu
Sep 19, 2012·Langmuir : the ACS Journal of Surfaces and Colloids·Reinhard VehringSarvajna K Dwivedi
Jun 1, 2013·The European Respiratory Journal·Eric D BatemanDonald Banerji
Jul 9, 2013·Respiratory Medicine·J F DonohueA Church
Jan 5, 2014·Chest·Bartolome CelliAlison Church
Nov 19, 2014·BMC Pulmonary Medicine·Dave SinghAnne Leselbaum
Jan 13, 2015·The European Respiratory Journal·Roland BuhlEric Bateman
Mar 11, 2015·Respiratory Research·Anthony D D'UrzoUNKNOWN AUGMENT COPD study investigators
Jul 16, 2015·American Journal of Respiratory and Critical Care Medicine·Donald A MahlerDonald Banerji
Aug 11, 2015·Annals of Internal Medicine·Wendy P BattistiYvonne E Yarker
Nov 2, 2015·Respiratory Investigation·Saeko Takahashi, Tomoko Betsuyaku
Apr 20, 2016·PloS One·Jason FooYogesh Punekar
Dec 6, 2016·Chest·Fernando J MartinezColin Reisner
Jan 8, 2017·Respiratory Research·Colin ReisnerSarvajna Dwivedi
Apr 22, 2017·Respiratory Medicine·Nicola A HananiaColin Reisner
Aug 20, 2017·Respiratory Research·Colin ReisnerUbaldo Martin
Aug 22, 2017·The Lancet. Respiratory Medicine·UNKNOWN GBD 2015 Chronic Respiratory Disease Collaborators
Sep 19, 2017·Lancet·UNKNOWN GBD 2016 Causes of Death Collaborators
Oct 12, 2017·AAPS PharmSciTech·Amber DotyPeter Mack
Apr 3, 2018·International Journal of Chronic Obstructive Pulmonary Disease·Gary T FergusonUbaldo J Martin
Apr 27, 2018·International Journal of Chronic Obstructive Pulmonary Disease·Yasushi FukushimaColin Reisner
May 5, 2018·Respiratory Medicine·Faisal FakihUbaldo J Martin
Oct 13, 2018·International Journal of Chronic Obstructive Pulmonary Disease·Brian J LipworthUbaldo J Martin
Citations
Aug 31, 2019·Drugs·Zaina T Al-Salama, James E Frampton
Dec 7, 2018·The Cochrane Database of Systematic Reviews·Yuji ObaSofia Dias
Aug 11, 2020·Expert Review of Respiratory Medicine·Pierre-Edouard GrilletArnaud Bourdin
Apr 16, 2019·Clinical Therapeutics·Qian ChenPaul Dorinsky